GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel CTNNB1 rearrangement.


Journal

Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329

Informations de publication

Date de publication:
03 2019
Historique:
received: 18 07 2018
revised: 14 10 2018
accepted: 16 10 2018
pubmed: 24 10 2018
medline: 22 3 2019
entrez: 24 10 2018
Statut: ppublish

Résumé

Mutations of CTNNB1 have been implicated in tumorigenesis in many organs. However, tumors harboring a CTNNB1 translocation are extremely rare and this translocation has never been reported in a uterine mesenchymal neoplasm. We report a novel translocation t(2;3)(p25;p22) involving the GREB1 (intron 8) and CTNNB1 (exon 3) in a uterine tumor resembling ovarian sex cord tumor (UTROSCT), which exhibited extrauterine metastasis. The translocation detected by RNA-sequencing was validated by RT-PCR, and resulted in nuclear expression of β-catenin. Juxtapositioning with GREB1, which is overexpressed in response to estrogens, resulted in overexpression of a truncated and hypophosphorylated nuclear β-catenin in the primary and recurrent tumors. This accumulation of nuclear β-catenin results in a constitutive activation of the Wnt/β-catenin signaling pathway with a major oncogenic effect. The CTNNB1 gene fusion, promoted by an estrogen-responsive gene (GREB1), could be a potential driver of tumorigenesis in this case and a therapeutic target with adapted inhibitors. RT-PCR and immunohistochemistry performed on 11 additional UTROSCTs showed no CTNNB1 fusion transcript or nuclear β-catenin immunoreactivity.

Identifiants

pubmed: 30350331
doi: 10.1002/gcc.22694
doi:

Substances chimiques

CTNNB1 protein, human 0
GREB1 protein, human 0
Neoplasm Proteins 0
Oncogene Proteins, Fusion 0
beta Catenin 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

155-163

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Sabrina Croce (S)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Tom Lesluyes (T)

Comprehensive Cancer Center, INSERM U1218, Institut Bergonié, Bordeaux, France.
University of Bordeaux, Bordeaux, France.
Cancer Research Center of Toulouse, Oncosarc, INSERM UMR1037, Toulouse, France.
Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

Lucile Delespaul (L)

University of Bordeaux, Bordeaux, France.
Cancer Research Center of Toulouse, Oncosarc, INSERM UMR1037, Toulouse, France.

Benjamin Bonhomme (B)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Gaëlle Pérot (G)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Valérie Velasco (V)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Laetitia Mayeur (L)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Flora Rebier (F)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Houda Ben Rejeb (H)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Frédéric Guyon (F)

Department of Surgery, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

W Glenn McCluggage (WG)

Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom.

Anne Floquet (A)

Department of Oncology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Denis Querleu (D)

University of Bordeaux, Bordeaux, France.
Department of Surgery, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Camille Chakiba (C)

Department of Oncology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Mojgan Devouassoux-Shisheboran (M)

Department of Pathology, CHU Lyon Sud, Pierrebenite, France.

Eliane Mery (E)

Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

Laurent Arnould (L)

Department of Pathology, Centre JF Leclerc, Comprehensive Cancer Center, Dijon, France.

Gerlinde Averous (G)

Department of Pathology, CHU Strasbourg, France.

Isabelle Soubeyran (I)

Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

Sophie Le Guellec (S)

Cancer Research Center of Toulouse, Oncosarc, INSERM UMR1037, Toulouse, France.
Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

Frédéric Chibon (F)

Cancer Research Center of Toulouse, Oncosarc, INSERM UMR1037, Toulouse, France.
Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH